Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
about
Pro-apoptotic activity of α-bisabolol in preclinical models of primary human acute leukemia cellsEffects of nilotinib on regulatory T cells: the dose mattersSystematic review of dasatinib in chronic myeloid leukemiaAntitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 studyProfile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemiaChemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemiaRoles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistanceAP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistanceSequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potencyStructural reengineering of imatinib to decrease cardiac risk in cancer therapyIdentification and characterization of the role of c-terminal Src kinase in dengue virus replicationNew Developments in Chronic Myeloid Leukemia: Implications for TherapyMouse models for radiation-induced cancersChronic myeloid leukemia: reminiscences and dreamsEuropean LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaTransfer RNA-derived small RNAs in the cancer transcriptomeManagement of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors TreatmentMolecular mechanisms for survival regulation of chronic myeloid leukemia stem cellsKinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitorsEpigenetics advancing personalized nanomedicine in cancer therapyResistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment optionsCrystal structures of the Lyn protein tyrosine kinase domain in its Apo- and inhibitor-bound stateStructural and Spectroscopic Analysis of the Kinase Inhibitor Bosutinib and an Isomer of Bosutinib Binding to the Abl Tyrosine Kinase DomainMEK1 mutations confer resistance to MEK and B-RAF inhibition.Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.Ponatinib in refractory Philadelphia chromosome-positive leukemias.Fyn: a novel molecular target in cancerEffective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanismHypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cellsCombination of two but not three current targeted drugs can improve therapy of chronic myeloid leukemiaOptimizing combination therapies with existing and future CML drugsChronic myeloid leukemia patients sensitive and resistant to imatinib treatment show different metabolic responsesEvolution of resistance to Aurora kinase B inhibitors in leukaemia cellsIntracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cellsWinHAP: an efficient haplotype phasing algorithm based on scalable sliding windowsRandom mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitorA target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALLATRA-induced cellular differentiation and CD38 expression inhibits acquisition of BCR-ABL mutations for CML acquired resistanceInhibition of Aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and Aurora kinases R763/AS703569 and PHA-739358 in BCR-ABL transformed cellsThe Chromatin Regulator CHD8 Is a Context-Dependent Mediator of Cell Survival in Murine Hematopoietic Malignancies
P2860
Q27906817-60E8DC07-454B-4346-9BEA-318AA8DEE05BQ29938345-83B391EC-B76E-4388-A9B9-0C5B11E67384Q29938523-0287B4EB-CC3A-4FF0-93FD-290B1D1C6E8FQ29938702-B2AB518A-CA35-494E-AB01-6ED9403FDCA3Q29938707-45809FCB-DA14-41EE-8E62-BE65BC1CC504Q32964883-07A2CC74-3AF1-4561-9B1E-1C07389DB702Q32964888-29C95C9A-5F54-4809-9CF5-8AD3A2C1FA8FQ32965008-7DABE824-2EC7-46CF-B96D-D9636C822B03Q86217599-26E26A59-DDD5-47BA-9BBA-7C8B91BCE3A1Q86217628-CF9E4E57-A790-437F-8B2E-AAFA202C45F5Q88412548-91B4EEEC-9FA0-4C00-8388-92E7202FBCDF
P1310
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
P248
Q21245461-5BEDA427-F893-45B9-9CDB-8D8223936996Q21245709-FBAB63F0-A7E8-44B5-9563-36C5AF75737DQ24596026-14C9C41F-7247-4C3D-BAAE-05CE2B2F8A48Q24596926-DF87A2E9-7DCD-43AF-B0A8-FBACAA80FDCBQ24607114-3F21C22E-DCFD-4708-89C5-1CD97FB4FA6FQ24622397-BA6C0B4F-3C1E-40B9-9855-A0D7DE18CF97Q24645668-345B9729-5C5E-4902-B6E0-A57CACAC3F44Q24648017-EB2DF372-2699-4454-A8A4-8EC3F121BA2AQ24681743-D20FEA63-6789-44B5-BBD5-B7A92D6D5501Q24685557-46ED847A-65E2-465F-BB58-FBBBE2548349Q26700106-CD9BEAC6-A4E5-4846-BFEA-189150668FFBQ26745669-EC630385-636F-46C6-B8B9-16B10F882091Q26747129-8CCE10EA-029F-43DC-A021-963B72D85321Q26748769-A84FD078-0D4F-4F12-8D1D-9AE980A4A59FQ26749324-554E74B7-3FB5-485E-99D8-163EB03CA27BQ26752293-837D8379-F54D-4210-AF9C-020491581F22Q26766299-C799225A-7E46-4496-B375-A2DB5A701F66Q26828528-0BFFD66D-D917-44E6-9707-799E10734FFDQ26849792-3DB6D1B5-D513-4035-B92D-8DAFE730766EQ27010637-879BC25C-3711-4713-AEC0-098E24F09F77Q27028181-B6AB3A28-4722-458F-85F1-CBC7F6E3D683Q27652762-7EAB5381-B0F8-43C4-9FCB-B735984EEE14Q27678454-7C94CD2B-9666-4542-B7F7-D7C5DA12DF42Q27777362-2CF71889-D514-41A8-B0D3-EF0B688F11C8Q27851450-AD76A89D-C023-4D10-858F-AFBE3B9FBA96Q27851967-FDEE91B3-8FDE-4C70-9608-B5B9D27BFE1FQ28273098-93A06EA0-6A05-484A-A57D-C15A2933F184Q28275023-A7845E1D-0C90-4EFB-8517-DD20147B8583Q28393898-A759639F-18F3-40CE-8A9E-03E439D1528BQ28474737-8B402BB5-3F0A-4D1E-A387-154E18178B13Q28475255-08BB2A34-D874-47DD-8C80-08DB7BFC1AE1Q28475717-6FCD12B9-FEF4-4841-A536-07CF6F5FCD24Q28480926-49CE4080-BAF6-41B2-AAEE-2168ED2213EAQ28481327-DE5EFF93-8015-4DD2-914E-000A6F4B14D5Q28482238-731D2384-088C-4482-92EF-976D1095506FQ28482297-069177F1-17A4-42A1-ADF4-2952611E2681Q28534337-D42C6059-032F-49F6-AE92-7F7802227C62Q28540033-919A2B39-271D-487C-940E-C365D072064AQ28545195-BF47194E-E9FD-4E82-86C1-3B55B986427DQ28551057-10EA09A1-B424-4EC0-91AD-ADCA5DDF8435
P2860
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
@ast
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
@en
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
@nl
type
label
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
@ast
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
@en
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
@nl
prefLabel
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
@ast
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
@en
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
@nl
P2093
P50
P3181
P356
P1476
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
@en
P2093
Arthur P Decillis
Charles L Sawyers
Claude Nicaise
Eric Bleickardt
John Nicoll
M Anne Blackwood-Chirchir
Moshe Talpaz
Neil P Shah
Nicholas Donato
P304
P3181
P356
10.1056/NEJMOA055229
P407
P577
2006-06-15T00:00:00Z